article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.

article thumbnail

What GLP-1 drugs mean for medtech

Clarivate

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. Device-based treatments for comorbidities associated with obesity will also see an impact. You can register for the webinar here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

article thumbnail

ANeuroTech shares plans for major depressive disorder pivotal programme

Pharmaceutical Technology

Belgium-headquartered ANeuroTech is participating in a Series B round, which will raise up to $150m to power the pivotal programme of its lead candidate ANT01 for use as an adjunctive treatment for major depressive disorder (MDD). The company aims to run an interim analysis of the trial by mid-2024 at the very latest.

article thumbnail

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

It is a challenging proposition, however, as delivery of the therapeutic gene sequences to cells can be difficult and raises the risk of insertion mutations that can lead to side effects, including cancer.

article thumbnail

Immutep’s LAG-3 drug ‘dramatically undervalued,’ says analyst

pharmaphorum

month mPFS with Keytruda plus chemo, with fewer side effects. A key readout for BMS will be a front-line phase 2 study of its combination in NSCLC due to read out in 2024, but its unclear if that could support approval so Immutep could be able to maintain a lead in this type of cancer.